DiaSorin S.p.A
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/sepsis, bone metabolism, and oncology under L… Read more
DiaSorin S.p.A (DSRLF) - Total Liabilities
Latest total liabilities as of June 2025: $1.34 Billion USD
Based on the latest financial reports, DiaSorin S.p.A (DSRLF) has total liabilities worth $1.34 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DiaSorin S.p.A - Total Liabilities Trend (2003–2024)
This chart illustrates how DiaSorin S.p.A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DiaSorin S.p.A Competitors by Total Liabilities
The table below lists competitors of DiaSorin S.p.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cinemark Holdings Inc
NYSE:CNK
|
USA | $4.04 Billion |
|
Vista Energy S.A.B. de C.V.
BA:VIST
|
Argentina | AR$1.40 Billion |
|
CarGurus
NASDAQ:CARG
|
USA | $287.70 Million |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
USA | $336.81 Million |
|
Sasol Limited
PINK:SASOF
|
USA | $201.94 Billion |
|
Munters Group AB
ST:MTRS
|
Sweden | Skr14.86 Billion |
|
Beijing Tricolor Technology Co Ltd
SHG:603516
|
China | CN¥123.84 Million |
Liability Composition Analysis (2003–2024)
This chart breaks down DiaSorin S.p.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DiaSorin S.p.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DiaSorin S.p.A (2003–2024)
The table below shows the annual total liabilities of DiaSorin S.p.A from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.51 Billion | -10.01% |
| 2023-12-31 | $1.67 Billion | -11.38% |
| 2022-12-31 | $1.89 Billion | +1.35% |
| 2021-12-31 | $1.86 Billion | +542.21% |
| 2020-12-31 | $290.13 Million | +34.99% |
| 2019-12-31 | $214.93 Million | +6.82% |
| 2018-12-31 | $201.21 Million | -1.26% |
| 2017-12-31 | $203.77 Million | -0.71% |
| 2016-12-31 | $205.23 Million | +69.97% |
| 2015-12-31 | $120.75 Million | -1.12% |
| 2014-12-31 | $122.12 Million | +8.57% |
| 2013-12-31 | $112.48 Million | -28.33% |
| 2012-12-31 | $156.94 Million | +27.57% |
| 2011-12-31 | $123.02 Million | -6.58% |
| 2010-12-31 | $131.69 Million | +10.62% |
| 2009-12-31 | $119.05 Million | +7.67% |
| 2008-12-31 | $110.57 Million | +25.57% |
| 2007-12-31 | $88.06 Million | -17.20% |
| 2006-12-31 | $106.34 Million | -38.36% |
| 2005-12-31 | $172.54 Million | +38.08% |
| 2004-12-31 | $124.96 Million | -7.18% |
| 2003-12-31 | $134.63 Million | -- |